Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trinity College (Dublin)

Latest From Trinity College (Dublin)

Ensysce Biosciences Inc.

Ensysce Biosciences Inc. is developing a nanoscaled delivery system that might work for many types of potential drugs but will first be applied to siRNAs, a class of drug candidates that inspired tremendous excitement a decade ago, but has since been abandoned by many of its former champions. The Houston, TX-based start-up believes it can harness single-walled carbon nanotubes to deliver siRNAs that will block or “silence” the genetic instructions encoded by messenger RNA, and thereby stop targeted genes from producing disease-related protein.

BioPharmaceutical Nanotechnology

IL-17: Pushing The Limits Of A Drug Target

A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.

BioPharmaceutical Research and Development Strategies

Recent Financings Of Private Companies, June 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device

Irish Biotech Opsona Adds Two New Corporate VCs In $43M Series C

Irish biotech Opsona Therapeutics recently raised $43 million with the help of four corporate VCs, for use in developing its potential first-in-class product for preventing delayed graft function in high-risk renal transplant patients.

BioPharmaceutical Ireland
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register